Hirschsprung’s Disease — Clinical Documentation Guide (2026)

🔍 Definition

Hirschsprung's disease (HD) — also known as congenital aganglionic megacolon — is a congenital developmental disorder of the enteric nervous system in which ganglion cells fail to migrate fully from the neural crest during fetal development (weeks 4–12 of gestation). The result is a segment of distal bowel that is permanently devoid of myenteric (Auerbach's) and submucosal (Meissner's) plexus ganglion cells, causing tonic contraction of the affected segment, functional intestinal obstruction, and progressive proximal colonic dilatation (StatPearls – Hirschsprung Disease).

The aganglionic segment always begins at the internal anal sphincter and extends proximally for a variable distance. In approximately 80% of cases only the rectosigmoid colon is involved (short-segment disease); in 15–20% the aganglionosis extends to the descending or transverse colon (long-segment disease); and in roughly 5% the entire colon — and occasionally portions of the small bowel — lack ganglion cells (total colonic aganglionosis, TCA) (American Academy of Family Physicians – AFP 2006; PubMed – Outcome of TCA, 2022).

HD occurs in approximately 1 per 5,000 live births with a 4:1 male-to-female predominance in short-segment disease (the sex ratio approaches 1:1 in total colonic forms). Associations include trisomy 21 (Down syndrome) in ~10–15% of cases, Waardenburg syndrome, and multiple endocrine neoplasia type 2A (RET proto-oncogene mutations are found in 35% of sporadic and ~50% of familial HD cases) (World Journal of Pediatric Surgery, 2025).

ICD-10-CM classifies HD under Q43.1 — Hirschsprung's disease, which captures aganglionosis and congenital aganglionic megacolon. Code Q43.1 may be applied to patients of any age; a congenital condition persisting throughout life retains its Chapter 17 congenital code per FY2026 ICD-10-CM Official Guidelines, Section I.C.17.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Presentation varies with age and segment length. Key clinical findings include (StatPearls; AAFP AFP 2006):

Neonates / Infants:

• Failure to pass meconium within 48 hours of birth — present in up to 90% of affected neonates; strongest early indicator
• Abdominal distension; bilious emesis
• Explosive discharge of gas and stool upon rectal examination ("squirt sign")
• Tight anal sphincter on digital exam
• Poor feeding, vomiting, obstipation
• Hirschsprung-associated enterocolitis (HAEC): fever, foul-smelling bloody or watery diarrhea, toxic appearance, abdominal tenderness; most dangerous complication (17–50% incidence)

Older Children / Adults (delayed diagnosis):

• Chronic progressive constipation refractory to laxatives
• Recurrent fecal impaction
• Failure to thrive, poor weight gain, malnutrition
• Overflow diarrhea (often misdiagnosed as functional constipation or IBS)
• Abdominal distension; palpable fecal mass

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

The following clinical indicators support coding of Hirschsprung's disease and related complications. CDI specialists should look for all of these in the medical record:

🦴 Anatomy & Pathophysiology

Normal enteric nervous system (ENS): The ENS comprises two ganglion cell plexuses within the bowel wall — the myenteric (Auerbach's) plexus between the circular and longitudinal smooth muscle layers, and the submucosal (Meissner's) plexus in the submucosa. Together they coordinate peristalsis and the rectoanal inhibitory reflex (RAIR), allowing the internal anal sphincter to relax in response to rectal distension (World Journal of Pediatric Surgery, 2025).

Pathophysiology of HD: During weeks 4–12 of gestation, vagal neural crest cells (NCCs) migrate craniocaudally along the intestine. Disruption of NCC migration, proliferation, or differentiation results in failure to colonize the distal bowel. The aganglionic segment lacks inhibitory neurons (VIP, NO-producing), leaving unopposed cholinergic (acetylcholine) excitatory tone — the bowel segment is tonically contracted and does not relax. Stool accumulates proximally, leading to progressive dilation of the normally innervated proximal colon (StatPearls).

Genetics: HD is multigenic. Mutations in the RET proto-oncogene account for 35% of sporadic cases and ~50% of familial HD. Other implicated genes include GDNF, EDNRB, endothelin-3 (EDN3), SOX10, and PHOX2B. HD can occur as isolated or syndromic (10% with trisomy 21; associations with Waardenburg-Shah, Mowat-Wilson, Goldberg-Shprintzen, and central hypoventilation syndromes) (World Journal of Pediatric Surgery, 2025).

Disease extent and transition zone:

• Short-segment HD (~80%): Aganglionosis limited to rectosigmoid junction
• Long-segment HD (~15–20%): Aganglionosis extends proximal to sigmoid colon
• Total colonic aganglionosis (TCA) (~5%): Entire colon affected; may extend into small bowel; complex surgical management; higher risk of short bowel syndrome

The transition zone (TZ) — the point where normal ganglionated bowel transitions to aganglionic bowel — appears radiographically as a "funnel" or "cone" on contrast enema, though the histological TZ extends 2–4 cm beyond the radiographic one, requiring intraoperative frozen sections to confirm clear margins (APSA Pediatric Surgery Library).

💊 Medication Impact / Treatment

Hirschsprung's disease is fundamentally a surgical condition — no pharmacological agent corrects aganglionosis. Medical management is supportive and directed at complications, particularly HAEC.

Pre-operative / Bridging management:

• Rectal irrigations (bowel washouts): Daily saline rectal irrigation decompresses the obstructed colon, prevents acute HAEC, and prepares the bowel for pull-through surgery. Typically administered by trained parents or nurses.
• Nasogastric decompression: For acute obstruction episodes.
• Nutritional support: Parenteral nutrition (PN) or enteral feeding in neonates with severe obstruction or TCA; coding impact: Z79.01 (long-term PN) if applicable.

Treatment of HAEC:

• Grade I (possible HAEC): Outpatient oral metronidazole, oral fluids/electrolytes
• Grade II–III (definite/severe HAEC): Inpatient admission; IV fluid resuscitation; broad-spectrum IV antibiotics (metronidazole + vancomycin or ampicillin + gentamicin); rectal irrigations every 6–8 hours; ICU for septic shock; emergent colostomy if refractory (StatPearls)

Post-operative pharmacology:

• Prophylactic rectal irrigation post-pull-through to reduce HAEC recurrence
• Botulinum toxin A (Botox) injection into the internal anal sphincter for persistent post-pull-through obstructive symptoms (internal anal sphincter achalasia) — CPT 46505
• Stool softeners (polyethylene glycol, lactulose) for post-operative constipation
• Loperamide for high-stool frequency post-TCA pull-through

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides